Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Novartis (SWX:NOVN) is expanding its US manufacturing and research footprint to support advanced therapies, including radioligand and RNA-based treatments.
The company recently received European Commission approval for Rhapsido, a first-in-class oral treatment for chronic spontaneous urticaria.
These moves add a new immunology product in Europe and increase US-based production capacity for complex therapies.
Novartis, a large global pharmaceuticals company, is best known for prescription drugs across oncology, cardiovascular, neuroscience, and immunology. The new US investments in manufacturing and research facilities extend that focus into advanced modalities, while Rhapsido adds another product to its immunology portfolio in Europe. For investors watching SWX:NOVN, these developments sit alongside prior headlines on earnings, acquisitions, and AI-driven research as part of a broader corporate trajectory.
For readers, the key question is how additional US capacity and a new European therapy could influence Novartis’s mix of growth drivers over time. The US buildout may affect supply reliability and cost structure for complex drugs, while Rhapsido positions the company with an oral option in chronic spontaneous urticaria that may appeal to certain patients and physicians. Both elements are likely to be important reference points when you assess how the portfolio might evolve across regions and therapeutic areas.
Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.
SWX:NOVN Earnings & Revenue Growth as at May 2026
📰 Beyond the headline: 1 risk and 3 things going right for Novartis that every investor should see.
The recent US manufacturing buildout and the European approval of Rhapsido give you more context for how Novartis is trying to balance its near term guidance with longer term priorities. On the one hand, the company has reaffirmed 2026 expectations for low single digit net sales growth and a low single digit decline in core operating income, while first quarter sales of US$13,113m and net income of US$3,156m were slightly below the prior year. On the other hand, a US$23,000m commitment to US-based manufacturing, including new facilities for radioligand therapies and RNA therapeutics, is aimed at securing capacity for complex drugs that competitors such as Roche, Pfizer and Merck are also targeting. In Europe, Rhapsido gives Novartis a first in class oral chronic spontaneous urticaria treatment at a time when more than half of patients are described as insufficiently served by antihistamines. For you, the key question is whether this combination of added capacity and new products supports the broader thesis that advanced therapies and portfolio refresh can offset generic erosion and margin pressure over time.
How This Fits Into The Novartis Narrative
The US facility expansion and Rhapsido approval fit with the narrative that advanced therapies and new launches can support growth alongside an aging global population and a rising chronic disease burden.
The scale of US$23,000m in US-focused manufacturing investment, on top of late stage pipeline spending, could weigh on margins in the near term and tests the assumption that operational efficiency alone drives margin expansion.
The narrative emphasizes emerging markets and share buybacks more than supply-chain moves such as US end to end manufacturing and radioligand capacity, which may affect resilience and capital needs in ways not fully reflected.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novartis to help decide what it’s worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Large, multi year US manufacturing investments could strain cash flows if new facilities run below capacity or if pricing pressure in key markets limits returns on that spend.
⚠️ Analysts have highlighted loss of exclusivity and generic competition as key risks, so even with Rhapsido and other launches, older products could lose revenue faster than newer ones contribute.
🎁 The buildout across North Carolina, Texas, Florida and California, plus expansions in Indiana and New Jersey, may support more reliable supply of radioligand and RNA therapies for US patients.
🎁 Rhapsido gives Novartis a differentiated oral option in chronic spontaneous urticaria, a condition affecting nearly 4m people in Europe, which broadens the immunology portfolio alongside gene and cell therapy programs.
What To Watch Going Forward
From here, watch how quickly the new US sites progress from construction to commercial production and whether management provides updates on utilization and capital efficiency. Track how Rhapsido uptake in Europe develops relative to existing chronic spontaneous urticaria options and whether it gains traction in treatment guidelines and reimbursement decisions. It is also worth following how these moves show up in reported net sales, core operating income and any commentary on generic erosion on the Q1 2026 earnings call and later updates, especially given the reaffirmed full year guidance.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novartis, head to the community page for Novartis to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com